Related Experiment Video

Updated: Jan 9, 2026

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

739

MarvelD3 regulates the radiosensitivity of Esophageal squamous cell carcinoma via the MYB/IFI6 axis

Xi Wang1, Jinming Cao2, Kaixiao Zhou3

  • 1School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou 215123, China; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China.

Cellular Signalling
|November 30, 2025
PubMed

Insights

MarvelD3 protein is overexpressed in esophageal squamous cell carcinoma (ESCC), impacting radiosensitivity. Targeting the MarvelD3/MYB/IFI6 pathway may improve ESCC treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Tight junction proteins are crucial in disease progression.
  • MarvelD3, a MARVEL domain protein, influences tight junctions but its role in esophageal squamous cell carcinoma (ESCC) is unknown.

Purpose of the Study:

  • To investigate the role of MarvelD3 in ESCC.
  • To determine MarvelD3's effect on ESCC radiosensitivity.
  • To elucidate the molecular mechanism involving MarvelD3 in ESCC.

Main Methods:

  • Analysis of MarvelD3 expression in ESCC tissues.
  • In vitro and in vivo knockdown of MarvelD3.
  • RNA-sequencing to identify MarvelD3 targets.
  • Co-immunoprecipitation, dual-luciferase reporter assays, and chromatin immunoprecipitation assays to study protein interactions and gene regulation.

Main Results:

  • MarvelD3 is significantly overexpressed in ESCC.
  • MarvelD3 knockdown increases radiosensitivity in ESCC models.
  • IFI6 is identified as a direct target of MarvelD3.
  • A regulatory axis involving MarvelD3, MYB, and IFI6 was uncovered, with MYB directly regulating IFI6 transcription.

Conclusions:

  • MarvelD3 overexpression contributes to ESCC progression and radioresistance.
  • The MYB/IFI6 signaling pathway is a key mediator of MarvelD3's function in ESCC.
  • MarvelD3 represents a potential therapeutic target for enhancing radiosensitivity in ESCC treatment.
Keywords:
ESCCIFI6MYBMarvelD3Radiation

More Related Videos

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

3.9K
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.3K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K